Intracranial Arterial Stenosis in Young Patients

NCT05844176 · tracked via the Priya Life Science China tracker

Sponsor

Capital Medical University

Phase

Observational

Started

2022-06-01

Last updated

2026-08-17

Condition(s) studied

Intracranial Arterial Stenosis

Investigational drug(s) / intervention(s)

Routine clinical treatment

Routine clinical treatment: Routine clinical treatment is based on the latest international and local guidelines

Study summary

The goal of this study is to evaluate the characteristic of intracranial arterial stenosis among young patients.

Eligibility

Sex

ALL

Min age

—

Max age

45 Years

Healthy volunteers

Inclusion Criteria: * age \< 45 years. * stenosis of a major intracranial artery. Exclusion Criteria: \-

Primary outcome measure(s)

Ischemic stroke in territory of qualifying artery — 1 year

Trial sites (4)

Facility	City	Region
Suzhou Municipal Hoapital	Suzhou	Anhui
The Second Hospital of Hebei Medical University	Shijiazhuang	Hebei
Xuanwu Hospital, Capital Medical University	Beijing	China
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China

More Capital Medical University trials in China

Telemedicine-supported Management for Acute Ischemic Stroke Recruiting

Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis Recruiting

Study on Biomarkers for Early Diagnosis of Alzheimer's Disease Recruiting

Effects of Tracheostomy Decannulation on Respiratory Function Recruiting

Intra-arterial Selective Hypothermic Magnesium Sulfate Infusion in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke Enrolling by invitation

Other trials for the same condition

Rapamycin-Eluting Vertebral Stents In The Real-World Treatment of Symptomatic Intracranial Atherosclerotic Stenosis Recruiting

Photon-counting CT for Intracranial Stent Assessment Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05844176 on ClinicalTrials.gov ↗ ← All trials in China